Jim Simons’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

Jim Simons’s Portfolio STSA Stock Details STSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-164,500	Closed	-$115K	–	4412
2023 Q1	$115K	Sell	164,500 -89,600	-35%	-$82.4K	﹤0.01%	3448
2022 Q4	$229K	Buy	254,100 +244,100	+2,441%	+$707K	﹤0.01%	3361
2022 Q3	$60K	Buy	+10,000	New	+$56.7K	﹤0.01%	3709
2021 Q4	–	Sell	-41,664	Closed	-$194K	–	4323
2021 Q3	$194K	Sell	41,664 -15,815	-28%	-$83.8K	﹤0.01%	3214
2021 Q2	$405K	Sell	57,479 -39,521	-41%	-$213K	﹤0.01%	3041
2021 Q1	$573K	Buy	97,000 +78,575	+426%	+$476K	﹤0.01%	2859
2020 Q4	$85K	Buy	+18,425	New	+$79.4K	﹤0.01%	3273

Jim Simons's STSA Position: Q2 2023 in Review

Jim Simons sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q2 2023, closing a stake of 164,500 shares — an estimated $115K sold.

Jim Simons first reported a position in STSA in Q4 2020 and held it in 7 quarters. The position peaked at $573K in Q1 2021. 0 funds tracked by Wall St. Rank hold STSA as of Q2 2023.

Jim Simons reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Jim Simons sold 164,500 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $115K.
Jim Simons first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q4 2020 and held it in 7 quarters.
Jim Simons's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $573K in Q1 2021.
0 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on Renaissance Technologies's 13F filing for Q2 2023, filed 11 Aug 2023.